Catheterization Lab Equipment in Washington

Cardiac Dimensions, Inc. is a medical device company focused on transcatheter treatment of functional mitral regurgitation (FMR) and heart failure. The company develops and commercializes the Carillon Mitral Contour System, a percutaneous, minimally invasive device designed to treat FMR by working with the heart's natural structure and function via coronary sinus-based mitral annuloplasty. The Carillon system is delivered through a catheter-based procedure typically lasting about one hour, without preventing access to other cardiac therapies. The device is CE-marked (0344) and commercially available in Europe and other jurisdictions. In the United States, the Carillon system is currently investigational, limited to clinical trials including the EMPOWER trial, which is enrolling heart failure patients with large ventricles and FMR. Multiple published European clinical studies demonstrate improvements in patient quality of life, mitral regurgitation severity, and left ventricular volume. The company serves interventional cardiologists, heart failure specialists, and hospital cardiology programs. As of 2025, Cardiac Dimensions has completed Series E financing ($53 million raised in March 2025) and appointed William T. Abraham, MD as Chief Medical Officer. The organization maintains headquarters in Kirkland, Washington, with operations in Europe (Offenbach, Germany) and Australia (Sydney). Clinical evidence includes multiple peer-reviewed publications in European Heart Journal, JACC: Cardiovascular Interventions, and other cardiology journals documenting long-term outcomes and mechanistic benefits of the Carillon therapy.

Carrot Medical develops integrated clinical visualization, secure streaming, wireless communication, and control systems for interventional labs, electrophysiology labs, and hybrid operating rooms. The company specializes in extending the useful life and operational efficiency of existing interventional infrastructure through software and hardware solutions that unify multiple imaging sources, enable encrypted HIPAA-compliant procedure documentation and remote collaboration, facilitate intra-team wireless communication in high-noise procedural environments, and centralize control of imaging and procedural devices. Primary products include C-View (large integrated clinical display), C-Suite Platinum (secure streaming and recording platform), C-Com (wireless medical headset system), and C-Control (KVM source control solution). Solutions are designed for cardiac catheterization labs, EP labs, and hybrid ORs serving hospital systems and procedural centers. The company maintains a customer base including regional medical centers such as St. Francis Medical Center, Fountain Valley Regional Hospital, Children's Mercy Hospital Kansas City, and San Jacinto Methodist Hospital. Carrot Medical provides installation, training, and ongoing customer support services.

Keya Medical is an international medical technology company founded in 2016, headquartered in Beijing with offices in Seattle, Shanghai, and Shenzhen. The company specializes in deep learning-based AI solutions for non-invasive disease diagnosis and treatment, with primary focus on cardiovascular care. Keya Medical develops AI-enabled diagnostic devices that enhance efficiency, accuracy, and precision in healthcare across cardiology, neurology, pulmonology, pathology, and surgery. The flagship product, DEEPVESSEL FFR, is a CT-derived fractional flow reserve (CT-FFR) analysis software that received FDA clearance (2022), CE marking (2018), NMPA approval (2020), and HSA certification (2023). This non-invasive tool reduces unnecessary invasive testing, improves patient safety, and lowers cardiovascular diagnostic costs. The company has secured over $111.74 million in funding and holds 11 registered patents related to artificial neural networks and medical imaging. Keya Medical established the first AI diagnostic laboratory and maintains collaborations with hospitals and key opinion leaders globally.

Astute Imaging is a healthcare IT solutions company specializing in AI-powered cardiovascular imaging software for image-guided therapy and precision medicine. Founded in 2021 as a spin-off from Fivos Health, the company develops a cloud-based SaaS platform that integrates with EMR, PACS, and clinical registries. The platform automates surgery planning, device recommendations, vascular modeling and finite element analysis, and patient follow-up tracking. Astute Imaging serves healthcare providers and medical device manufacturers, supporting over 2,500 surgeons across 1,000+ centers. Key offerings include PEMS® (Patient Tracking and Management System), Preview® surgical planning tools, and proprietary finite element analysis for aortic disease management. The platform leverages 25 years of annotated vascular imaging data and AI to enhance diagnostic accuracy, provider productivity, and patient outcomes while reducing time-to-market for medical device development.